# Stephen C. Bain

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stephen-c-bain/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,065 |
| Field | Diabetes Treatment and Management |
| h-index | 63 |
| i10-index | 181 |
| OpenAlex ID | https://openalex.org/A5080463002 |
| ORCID iD | 0000-0001-8519-4964 |
| Works | 415 |

## Researcher papers

Showing 12 of 16.

- [Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind/)
- [Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/oral-semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [A genome-wide search for human type 1 diabetes susceptibility genes](https://scholariq.org/papers/a-genome-wide-search-for-human-type-1-diabetes-susceptibility-genes/)
- [Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/angiotensin-receptor-blockade-versus-converting-enzyme-inhibition-in-type-2/)
- [3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial](https://scholariq.org/papers/3-years-of-liraglutide-versus-placebo-for-type-2-diabetes-risk-reduction-and/)
- [Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus](https://scholariq.org/papers/susceptibility-to-human-type-1-diabetes-at-iddm2-is-determined-by-tandem-repeat/)
- [Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial](https://scholariq.org/papers/efficacy-and-safety-of-once-weekly-semaglutide-monotherapy-versus-placebo-in/)
- [Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-renal-outcomes-in-type-2-diabetes-an-exploratory-analysis-of-the/)
- [Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial](https://scholariq.org/papers/efficacy-and-safety-of-once-weekly-semaglutide-versus-once-daily-insulin/)
- [Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes](https://scholariq.org/papers/oral-semaglutide-and-cardiovascular-outcomes-in-high-risk-type-2-diabetes/)
- [Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled-2/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes and associated disorders](https://scholariq.org/topics/diabetes-and-associated-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.